Lysophospholipids and their receptors in the central nervous system
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Ji Woong | - |
dc.contributor.author | Chun, Jerold | - |
dc.date.available | 2020-02-29T00:46:06Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2013-01 | - |
dc.identifier.issn | 1388-1981 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14831 | - |
dc.description.abstract | Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), two of the best-studied lysophospholipids, are known to influence diverse biological events, including organismal development as well as function and pathogenesis within multiple organ systems. These functional roles are due to a family of at least 11 G protein-coupled receptors (GPCRs), named LPA(1-6) and SIP1-5, which are widely distributed throughout the body and that activate multiple effector pathways initiated by a range of heterotrimeric G proteins including G(i/o), G(12/13), G(q) and G(s), with actual activation dependent on receptor subtypes. In the central nervous system (CNS), a major locus for these signaling pathways, LPA and SIP have been shown to influence myriad responses in neurons and glial cell types through their cognate receptors. These receptor-mediated activities can contribute to disease pathogenesis and have therapeutic relevance to human CNS disorders as demonstrated for multiple sclerosis (MS) and possibly others that include congenital hydrocephalus, ischemic stroke, neurotrauma, neuropsychiatric disorders, developmental disorders, seizures, hearing loss, and Sandhoff disease, based upon the experimental literature. In particular, FTY720 (fingolimod, Gilenya, Novartis Pharma, AG) that becomes an analog of S1P upon phosphorylation, was approved by the FDA in 2010 as a first oral treatment for MS, validating this class of receptors as medicinal targets. This review will provide an overview and update on the biological functions of LPA and SIP signaling in the CNS, with a focus on results from studies using genetic null mutants for LPA and SIP receptors. This article is part of a Special Issue entitled Advances in Lysophospholipid Research. (C) 2012 Published by Elsevier B.V. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.relation.isPartOf | BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | - |
dc.subject | LYSOPHOSPHATIDIC ACID RECEPTOR | - |
dc.subject | SPHINGOSINE 1-PHOSPHATE RECEPTOR | - |
dc.subject | PROTEIN-COUPLED RECEPTOR | - |
dc.subject | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | - |
dc.subject | OBVIOUS PHENOTYPIC ABNORMALITY | - |
dc.subject | MULTIPLE-SCLEROSIS | - |
dc.subject | SPHINGOSINE-1-PHOSPHATE RECEPTORS | - |
dc.subject | MICE LACKING | - |
dc.subject | IN-VIVO | - |
dc.subject | FINGOLIMOD FTY720 | - |
dc.title | Lysophospholipids and their receptors in the central nervous system | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000311596600004 | - |
dc.identifier.doi | 10.1016/j.bbalip.2012.07.015 | - |
dc.identifier.bibliographicCitation | BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, v.1831, no.1, pp.20 - 32 | - |
dc.identifier.scopusid | 2-s2.0-84868576848 | - |
dc.citation.endPage | 32 | - |
dc.citation.startPage | 20 | - |
dc.citation.title | BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | - |
dc.citation.volume | 1831 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Choi, Ji Woong | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Lysophosphatidic acid | - |
dc.subject.keywordAuthor | Sphingosine 1-phosphate | - |
dc.subject.keywordAuthor | G protein-coupled receptor | - |
dc.subject.keywordAuthor | Central nervous system | - |
dc.subject.keywordAuthor | CNS disease | - |
dc.subject.keywordPlus | LYSOPHOSPHATIDIC ACID RECEPTOR | - |
dc.subject.keywordPlus | SPHINGOSINE 1-PHOSPHATE RECEPTOR | - |
dc.subject.keywordPlus | PROTEIN-COUPLED RECEPTOR | - |
dc.subject.keywordPlus | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | - |
dc.subject.keywordPlus | OBVIOUS PHENOTYPIC ABNORMALITY | - |
dc.subject.keywordPlus | MULTIPLE-SCLEROSIS | - |
dc.subject.keywordPlus | SPHINGOSINE-1-PHOSPHATE RECEPTORS | - |
dc.subject.keywordPlus | MICE LACKING | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | FINGOLIMOD FTY720 | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biophysics | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biophysics | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.